Oxford, United Kingdom - November 18, 2025

Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster. Founded in 2019, OXcan recently completed its Series A funding round, led by We Venture Capital and Cross-Border Impact Ventures.

Colin Brown, Development Director, Mission Street commented:

“We’re delighted to welcome OXcan as the newest occupier at Inventa. They are an exceptional company advancing the science of machine learning and diagnostics. OXcan is a valuable addition to the growing Inventa and West End ecosystem. Inventa is now nearing full occupancy, bringing together some of Oxford’s most exciting innovation companies and establishing the city’s only central research and development cluster.”

Dr. Andreas Halner, OXcan's President and Co-Founder, added:

“The new facility will enable OXcan to expand its analytical and laboratory capabilities, strengthen clinical collaborations, and advance our mission to deliver more accurate and accessible diagnostics to patients worldwide. We chose Inventa for its convenient proximity to central Oxford and the train station, offering access to top talent from Oxfordshire and beyond. The Mission Street team has been outstanding in supporting our transition, and we look forward to this next phase of growth and to contributing to the dynamic innovation ecosystem taking shape in Oxford’s West End.”

Both parties are eager to see OXcan’s presence at Inventa further enhance collaboration and advance the region’s innovation ecosystem. 

ENDS

About Mission Street

Mission Street was established in 2017 as an investor, developer and operator specialising in the sciences and innovation sector. Senior leadership has unrivalled experience and expertise in delivering science and Innovation buildings and is supported by an advisory board comprising industry leaders Peter Finan, Tim Funnell, Jonathan Hepple and Nick Sturge. The company is at various stages of developing a 1.5m sq ft pipeline in Oxford, Cambridge and Bristol. This includes the next available space to be delivered in the Oxford and Cambridge markets. The company is a proven innovator and market leader in the Innovation Real Estate sector, delivering successful and complex projects including both new-build R&D buildings and creative conversions of industrial and retail buildings.  

For more information, please visit www.mission-property.com 

About BGO   

BGO is a leading, global real estate investment management advisor, real estate lender, and a globally recognized provider of real estate services. BGO serves the interests of more than 750 institutional clients with approximately $83 billion USD of assets under management (as of December 31, 2024) and expertise in the asset management of office, industrial, multi-residential, retail and hospitality property across the globe. BGO has offices in 27 cities across thirteen countries with deep, local knowledge, experience, and extensive networks in the regions where we invest in and manage real estate assets on behalf of our clients in primary, secondary and co-investment markets. BGO is a part of SLC Management, which is the alternative asset management business of Sun Life.

The assets under management shown above includes real estate equity and mortgage investments managed by the BGO group of companies and their affiliates, and as of 1Q21, includes certain uncalled capital commitments for discretionary capital until they are legally expired and excludes certain uncalled capital commitments where the investor has complete discretion over investment.  

For more information, please visit www.bgo.com   

About Oxford Cancer Analytics (OXcan)

Oxford Cancer Analytics (OXcan) is an emerging diagnostics company that leverages advanced proteomics and machine learning to create innovative tests for earlier and more accurate assessment of lung diseases. Founded in Oxford, OXcan partners with leading research and clinical institutions to accelerate the translation of laboratory breakthroughs into improved patient care.

For more information, please visit www.oxcan.org and follow OXcan on LinkedIn. 

Media Contact:

Joshua Carson

SeniorConsultant

MontfortCommunications

carson@montfort.london

RosetteJoseph

Operationsand Communications Manager

OxfordCancer Analytics

r.joseph@oxcan.org

‍

‍